Patient preference in the management of postmenopausal osteoporosis with bisphosphonates

References

• BaroutsouBBabiolakisDStamatiadouA2004Patient compliance and preference of alendronate once weekly administration in comparison with daily regimens for osteoporotic postmenopausal womenAnn Rheum Dis63Suppl 1455
   Google Scholar
• BartlRGoetteSHadjiP2006Persistence and compliance with daily- and weekly-administered bisphosphonates in German women with osteoporosisAnn Rheum Dis64Suppl 3364
   Google Scholar
• BlackDMCummingsSRKarpfDB1996Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research GroupLancet3481535418950879
   PubMed Web of Science ®Google Scholar
• BrownJPKendlerDLMcClungMR2002The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosisCalcif Tissue Int711031112085156
   PubMed Web of Science ®Google Scholar
• CaroJJIshakKJHuybrechtsKF2004The impact of compliance with osteoporosis therapy on fracture rates in actual practiceOsteoporos Int151003815167989
   PubMed Web of Science ®Google Scholar
• CenterJRNguyenTVSchneiderD1999Mortality after all major types of osteoporotic fracture in men and women: an observational studyLancet3538788210093980
   PubMed Web of Science ®Google Scholar
• ChesnutCHSkagAChristiansenC2004Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisJ Bone Miner Res191241915231010
   PubMed Web of Science ®Google Scholar
• ChrischillesEAButlerCDDavisCS1991A model of lifetime osteoporosis impactArch Intern Med1512026321929691
   PubMed Web of Science ®Google Scholar
• CooperADrakeJBrankinE2006Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST studyInt J Clin Pract6089690516800837
   PubMed Web of Science ®Google Scholar
• CooperCCampionGMeltonLJIII1992Hip fractures in the elderly: a world-wide projectionOsteoporos Int228591421796
   PubMed Web of Science ®Google Scholar
• CowellWFulford-SmithAPoultneyS2005Adherence with bisphosphonate treatment for osteoporosis in UK patientsBone36Suppl 2S40910
   Google Scholar
• CramerJAAmonkarMHebbornA2004Assessing the relationship between bisphosphonate dosing regimen and treatment adherence among post-menopausal osteoporotic womenArthritis Rheum50SupplS294
   Google Scholar
• CramerJAAmonkarMMHebbornA2005Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosisCurr Med Res Opin2114536016197664
   PubMed Web of Science ®Google Scholar
• CranneyAWellsGWillanA2002II. Meta-analysis of alendronate for the treatment of postmenopausal womenEndocr Rev235081612202465
   PubMed Web of Science ®Google Scholar
• CummingsSRBlackDMThompsonDE1998Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialJAMA2802077829875874
   PubMed Web of Science ®Google Scholar
• CummingsSRMeltonLJ2002Epidemiology and outcomes of osteoporotic fracturesLancet3591761712049882
   PubMed Web of Science ®Google Scholar
• DelmasPDVrijensBVan de LangerjitL2003Effect of reinforcement with bone turnover marker results on persistence with risedronate treatment in postmenopausal women with osteoporosis: improving the measurements of persistence on actonel treatment (IMPACT) studyCalcif Tissue Int72335
   Google Scholar
• EastellRGarneroPVrijensB2003Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT studyCalcif Tissue Int72408
   Google Scholar
• EmkeyRKoltunWBeusterienK2005Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Bonviva Alendronate Trial in Osteoporosis (BALTO)Curr Med Res Opin21189590316368038
   PubMed Web of Science ®Google Scholar
• EttingerMGallagherRAmonkarM2004Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequateArthritis Rheum50SupplS513
   Google Scholar
• GoettschWGPenningFErkensJE2005Persistent bisphosphonate usage reduces the risk of hospitalizations for osteoporotic fracturesJ Bone Miner Res20Suppl 1S278
   Google Scholar
• HadjiPBenhamouCLDevasV2006Women with postmenopausal osteoporosis prefer once-monthly oral ibandronate to weekly oral alendronate: results of BALTO IIOsteoporos Int17Suppl 1S69
   Google Scholar
• HarrisSTSirisEAbbottT2005Reduced osteoporotic fracture risk in patients adherence to bisphosphonate therapyProgram & Abstracts of The Endocrine Society’s 87th Annual Meeting4–7 June 20053382
   Google Scholar
• HarrisSTWattsNBGenantHK1999Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupJAMA28213445210527181
   PubMed Web of Science ®Google Scholar
• HodgsonSFWattsNBBilezikianJP2003American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003Endocr Pract95446414715483
   PubMedGoogle Scholar
• IOF2003Osteoporosis in the European community: action plan [online]. Accessed 1 September 2006. URL: http://www.osteofound.org/advocacy_policy/eu_policy_project/pdf/action_plan_03_e.pdf#search=%22Osteoporosis%20in%20the%20European%20community%3A%20action%20plan%22
   Google Scholar
• IOF2005IOF adherence gap report [online]. Accessed 1 September 2006. URL: http://www.osteofound.org/publications/pdf/adherence_gap_report.pdf
   Google Scholar
• JahngKHMartinLRGolinCE2005Preferences for medical collaboration: patient-physician congruence and patient outcomesPatient Educ Couns573081415893213
   PubMed Web of Science ®Google Scholar
• JalavaTSarnaSPylkkanenL2003Association between vertebral fracture and increased mortality in osteoporotic patientsJ Bone Miner Res1812546012854835
   PubMed Web of Science ®Google Scholar
• JanzNKWrenPACopelandLA2004Patient-physician concordance: preferences, perceptions, and factors influencing the breast cancer surgical decisionJ Clin Oncol223091815284259
   PubMed Web of Science ®Google Scholar
• JohnellO1997The socioeconomic burden of fractures: today and in the 21st centuryAm J Med10320S5S9302894
   PubMedGoogle Scholar
• JohnellOKanisJAOdenA2004Mortality after osteoporotic fracturesOsteoporos Int15384214593451
   PubMed Web of Science ®Google Scholar
• JohnellOOdenACaulinF2001Acute and long-term increase in fracture risk after hospitalization for vertebral fractureOsteoporos Int122071411315239
   PubMed Web of Science ®Google Scholar
• KanisJAOdenAJohnellO2004Excess mortality after hospitalisation for vertebral fractureOsteoporos Int151081214598026
   PubMed Web of Science ®Google Scholar
• KendlerDKungAWFuleihan GelH2004Patients with osteoporosis prefer once weekly to once daily dosing with alendronateMaturitas482435115207890
   PubMed Web of Science ®Google Scholar
• LinPCampbellDGChaneyEE2005The influence of patient preference on depression treatment in primary careAnn Behav Med301647316173913
   PubMed Web of Science ®Google Scholar
• LipsP2003Invest in your bones: quality of Life. Why prevent the first fracture? International Osteoporosis Foundation [online]. Accessed 1 September 2006. URL: http://www.osteofound.org/publications/pdf/quality_of_life.pdf#search=%22Invest%20in%20your%20bones%3A%20quality%20of%20Life.%20Why%20prevent%20the%20first%20fracture%3F%22
   Google Scholar
• LipsPCooperCAgnusdeiD1999Quality of life in patients with vertebral fractures: validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO). Working Party for Quality of Life of the European Foundation for OsteoporosisOsteoporos Int101506010501796
   PubMed Web of Science ®Google Scholar
• LopesPRozenbergSde GraafJ2001Aerodiol versus the transdermal route: perspectives for patient preferenceMaturitas38Suppl 1S31911390122
   PubMed Web of Science ®Google Scholar
• MadhokRKerrHCapellHA2000Recent advances: rheumatologyBMJ321882511021871
   PubMed Web of Science ®Google Scholar
• McClungMRGeusensPMillerPD2001Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study GroupN Engl J Med3443334011172164
   PubMed Web of Science ®Google Scholar
• MeltonLJIII2000Who has osteoporosis? A conflict between clinical and public health perspectivesJ Bone Miner Res1523091411127196
   PubMed Web of Science ®Google Scholar
• MeltonLJIII2003Adverse outcomes of osteoporotic fractures in the general populationJ Bone Miner Res1811394112817771
   PubMed Web of Science ®Google Scholar
• MeltonLJIIIChrischillesEACooperC1992Perspective. How many women have osteoporosis?J Bone Miner Res71005101414493
   PubMed Web of Science ®Google Scholar
• MillerPDMcClungMMacoveiL2005Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE studyJ Bone Miner Res2013152216007327
   PubMed Web of Science ®Google Scholar
• NavesBaz-LopezJBGomezC2003The effects of vertebral fracture as a risk factor for osteoporotic fracture and mortality in a Spanish populationOsteoporos Int14520412730754
   PubMed Web of Science ®Google Scholar
• Penning-van BeestFGoettschWErkensJ2004Persistence with bisphosphonate therapy among post-menopausal osteoporotic women and the impact of dosing frequencyValue Health7724
   Web of Science ®Google Scholar
• ReckerRRGallagherRAmonkarAA2004Medication persistence is better with weekly bisphosphonates, but it remains suboptimalJ Bone Miner Res19Suppl 1S172
   Google Scholar
• ReckerRRGallagherRMacCosbePE2005Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of womenMayo Clin Proc808566116007889
   PubMed Web of Science ®Google Scholar
• ReginsterJYAdamiSLakatosP2006Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE studyAnn Rheum Dis656546116339289
   PubMed Web of Science ®Google Scholar
• ReginsterJYMinneHWSorensenOH2000Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study GroupOsteoporos Int11839110663363
   PubMed Web of Science ®Google Scholar
• RiisBJIseJvon SteinT2001Ibandronate: a comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosisJ Bone Miner Res161871811585352
   PubMed Web of Science ®Google Scholar
• RossP1997Clinical consequences of vertebral fracturesAm J Med10330S42S9302895
   PubMedGoogle Scholar
• RussellRGRogersMJ1999Bisphosphonates: from the laboratory to the clinic and back againBone259710610423031
   PubMed Web of Science ®Google Scholar
• SchnitzerTBoneHGCrepaldiG2000Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupAging (Milano)1211210746426
   PubMedGoogle Scholar
• SebaldtRJShaneLPhamB2004Longer-term effectiveness outcomes of non-compliance and non-persistence with daily-regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist careOsteoporos Int15Suppl 1S107
   Google Scholar
• SimonJABeusterienKMLeidyNK2005Women with postmenopausal osteoporosis express a preference for once-monthly versus once-weekly bisphosphonate treatmentFemale Patient30316
   Google Scholar
• SimonJALewieckiEMSmithME2002Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, cross-over studyClin Ther2418718612501880
   PubMed Web of Science ®Google Scholar
• SimpsonSHEurichDTMajumdarSR2006A meta-analysis of the association between adherence to drug therapy and mortalityBMJ333151816790458
   PubMed Web of Science ®Google Scholar
• SirisEHarrisSSilvermanS2005Adherence to bisphosphonates (BPs) is associated with reduced fracture risk in women with postmenopausal osteoporosis (PMO)Menopause12807
   Web of Science ®Google Scholar
• SunyeczJAGallagherRSmithJC2004Weekly dosing with bisphosphonates has higher, but suboptimal days of therapy17th World Conference of Family Doctors (WONCA 2004)13–17 October 2004
   Google Scholar
• [WHO] World Health Organization2003bAdherence to long-term therapies: evidence for actionWorld Health Organization1211
   Google Scholar
• [WHO] World Health Organization2003aPrevention and management of osteoporosisWorld Health Organ Tech Rep Ser9211164
   Web of Science ®Google Scholar